CorMedix Stock Forecast, Price & News

CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions

Is CorMedix a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CorMedix stock.
View analyst ratings for CorMedix or view top-rated stocks.

How has CorMedix's stock been impacted by Coronavirus (COVID-19)?

CorMedix's stock was trading at $5.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRMD stock has decreased by 1.8% and is now trading at $4.93.
View which stocks have been most impacted by COVID-19.

How were CorMedix's earnings last quarter?

CorMedix Inc. (NYSEAMERICAN:CRMD) issued its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.18) by $0.04. CorMedix had a negative trailing twelve-month return on equity of 39.16% and a negative net margin of 13,952.10%.
View CorMedix's earnings history.

When did CorMedix's stock split? How did CorMedix's stock split work?

CorMedix shares reverse split on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of CorMedix stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for CRMD?

3 analysts have issued 12-month price objectives for CorMedix's stock. Their forecasts range from $13.50 to $29.00. On average, they expect CorMedix's stock price to reach $20.50 in the next twelve months. This suggests a possible upside of 315.8% from the stock's current price.
View analysts' price targets for CorMedix or view top-rated stocks among Wall Street analysts.

Who are CorMedix's key executives?

CorMedix's management team includes the following people:

• Mathew David, Executive VP, Chief Executive & Financial Officer
• Antony E. Pfaffle, Secretary & Chief Scientific Officer
• Elizabeth Masson-Hurlburt, Executive Vice President & Head-Clinical Operation
• Phoebe Mounts, EVP, General Counsel, Head-Regulatory & Compliance
• Thomas Nusbickel, Chief Commercial Officer

Who are some of CorMedix's key competitors?

Some companies that are related to CorMedix include Janux Therapeutics (JANX), Kronos Bio (KRON), Akero Therapeutics (AKRO), Catalyst Pharmaceuticals (CPRX), Silence Therapeutics (SLN), Chinook Therapeutics (KDNY), Zogenix (ZGNX), Kezar Life Sciences (KZR), CytoDyn (CYDY), Northwest Biotherapeutics (NWBO), Prelude Therapeutics (PRLD), Dyne Therapeutics (DYN), Atea Pharmaceuticals (AVIR), Cara Therapeutics (CARA) and Radius Health (RDUS).
View all of CRMD's competitors.

What other stocks do shareholders of CorMedix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include ZIOPHARM Oncology (ZIOP), Rexahn Pharmaceuticals (REXN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Trevena (TRVN), Precigen (PGEN), Advanced Micro Devices (AMD), Kindred Biosciences (KIN), OPKO Health (OPK) and Sangamo Therapeutics (SGMO).

What is CorMedix's stock symbol?

CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."

Who are CorMedix's major shareholders?

CorMedix's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.58%), Geode Capital Management LLC (1.76%), Morgan Stanley (0.97%), Two Sigma Advisers LP (0.42%), Two Sigma Investments LP (0.34%) and Bank of New York Mellon Corp (0.32%). Company insiders that own CorMedix stock include Alan W Dunton, Elizabeth Masson-Hurlburt, Jr John L Armstrong, Khoso Baluch, Matthew T David, Mehmood Khan, Myron Kaplan, Phoebe Mounts and Steven W Lefkowitz.
View institutional ownership trends for CorMedix.

Which institutional investors are selling CorMedix stock?

CRMD stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, State Board of Administration of Florida Retirement System, Two Sigma Advisers LP, California State Teachers Retirement System, Jane Street Group LLC, Barclays PLC, Citadel Advisors LLC, and Private Advisor Group LLC.
View insider buying and selling activity for CorMedix or view top insider-selling stocks.

Which institutional investors are buying CorMedix stock?

CRMD stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, Geode Capital Management LLC, SG Americas Securities LLC, Advisory Services Network LLC, BlackRock Inc., Invesco Ltd., and Beacon Pointe Advisors LLC. Company insiders that have bought CorMedix stock in the last two years include Alan W Dunton, Jr John L Armstrong, Khoso Baluch, Matthew T David, Mehmood Khan, Myron Kaplan, Phoebe Mounts, and Steven W Lefkowitz.
View insider buying and selling activity for CorMedix or or view top insider-buying stocks.

How do I buy shares of CorMedix?

Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CorMedix's stock price today?

One share of CRMD stock can currently be purchased for approximately $4.93.

How much money does CorMedix make?

CorMedix has a market capitalization of $187.76 million and generates $240 thousand in revenue each year. The biotechnology company earns $-22.03 million in net income (profit) each year or ($0.73) on an earnings per share basis.

How many employees does CorMedix have?

CorMedix employs 35 workers across the globe.

What is CorMedix's official website?

The official website for CorMedix is www.cormedix.com.

Where are CorMedix's headquarters?

CorMedix is headquartered at 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States.

How can I contact CorMedix?

CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at (908) 517-9500 or via fax at 908-429-4307.